LOGIN  |  REGISTER
Astria Therapeutics

List of Biotechnology Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 447.26
-2.26 -0.50
866,690
253.72M
US$ 113.480B
US$ 748.71
-1.08 -0.14
861,354
103.28M
US$ 77.330B
US$ 396.04
3.94 1.00
1.49M
132.11M
US$ 52.320B
US$ 847.05
-15.38 -1.78
164,779
61.57M
US$ 52.150B
US$ 166.55
-31.91 -16.08
27.73M
213.27M
US$ 35.520B
US$ 91.46
-0.14 -0.15
1.69M
240.46M
US$ 21.990B
US$ 507.54
-3.40 -0.67
469,582
43.06M
US$ 21.850B
US$ 31.50
-0.21 -0.66
870,834
615.99M
US$ 19.400B
US$ 97.31
-0.32 -0.33
1.57M
196.32M
US$ 19.100B
US$ 184.71
0.00 0.00
0
97.68M
US$ 18.040B
US$ 38.43
0.12 0.31
2.15M
427.25M
US$ 16.420B
US$ 21.79
-0.91 -4.01
10.42M
695.49M
US$ 15.150B
US$ 75.96
-0.78 -1.02
3.43M
193.32M
US$ 14.680B
US$ 74.14
0.11 0.15
1.32M
192.71M
US$ 14.290B
US$ 141.84
0.14 0.10
1.18M
99.71M
US$ 14.140B
US$ 131.87
0.00 0.00
0
106.24M
US$ 14.010B
US$ 17.04
0.02 0.12
1.17M
744.44M
US$ 12.690B
US$ 77.63
0.55 0.71
1.62M
161.97M
US$ 12.570B
US$ 544.41
-1.78 -0.33
299,348
22.71M
US$ 12.360B
US$ 199.80
-3.02 -1.49
715,392
61.10M
US$ 12.210B
US$ 30.95
0.44 1.44
19.74M
390.73M
US$ 12.090B
US$ 42.57
0.57 1.36
1.61M
268.11M
US$ 11.410B
US$ 72.14
0.27 0.38
4.69M
150.68M
US$ 10.870B
US$ 166.00
1.08 0.65
937,249
60.77M
US$ 10.090B
US$ 28.66
0.15 0.53
2,607
349.00M
US$ 10.000B
US$ 51.95
0.15 0.29
1.74M
192.11M
US$ 9.980B
US$ 106.91
0.00 0.00
0
84.98M
US$ 9.090B
US$ 66.47
1.67 2.58
1.37M
135.81M
US$ 9.030B
US$ 57.10
0.11 0.19
1.34M
155.81M
US$ 8.900B
US$ 113.61
2.79 2.52
843,594
77.93M
US$ 8.850B
US$ 81.54
-0.74 -0.90
631,660
105.19M
US$ 8.580B
US$ 129.46
0.00 0.00
0
64.58M
US$ 8.360B
US$ 27.86
0.67 2.46
2.51M
282.15M
US$ 7.860B
US$ 65.11
-0.66 -1.00
1.57M
117.60M
US$ 7.660B
US$ 62.20
2.38 3.98
3.25M
122.26M
US$ 7.600B
US$ 111.73
-0.13 -0.12
883,191
66.74M
US$ 7.460B
US$ 147.00
-1.00 -0.68
271,565
50.41M
US$ 7.410B
US$ 96.80
-0.09 -0.09
1.14M
75.85M
US$ 7.340B
US$ 220.35
0.20 0.09
1.31M
31.45M
US$ 6.930B
US$ 101.41
0.16 0.16
346,409
67.27M
US$ 6.820B
US$ 233.37
-2.18 -0.93
166,663
29.00M
US$ 6.770B
US$ 269.26
3.40 1.28
265,565
25.01M
US$ 6.730B
US$ 79.63
-2.44 -2.97
733,659
80.00M
US$ 6.370B
US$ 37.90
-1.55 -3.93
3.59M
153.51M
US$ 5.820B
US$ 154.54
0.33 0.21
199,208
37.51M
US$ 5.800B
US$ 43.71
0.65 1.51
1.20M
130.91M
US$ 5.720B
US$ 85.79
-3.55 -3.97
1.71M
62.52M
US$ 5.360B
US$ 26.18
-0.80 -2.97
2.00M
201.48M
US$ 5.270B
US$ 54.85
0.11 0.20
1.02M
95.30M
US$ 5.230B
US$ 33.22
0.14 0.42
1.23M
145.68M
US$ 4.840B
US$ 29.93
-1.20 -3.85
1.39M
158.76M
US$ 4.750B
US$ 27.81
-0.22 -0.78
1.21M
165.12M
US$ 4.590B
US$ 99.16
0.15 0.15
582,411
46.27M
US$ 4.590B
US$ 26.60
-0.33 -1.23
1.16M
169.18M
US$ 4.500B
US$ 54.65
0.00 0.00
0
82.32M
US$ 4.500B
US$ 18.81
-0.02 -0.11
1.36M
238.00M
US$ 4.480B
US$ 42.93
-1.08 -2.45
1.13M
102.01M
US$ 4.380B
US$ 62.45
2.48 4.14
1.06M
69.14M
US$ 4.320B
US$ 45.14
-2.55 -5.35
1.87M
94.89M
US$ 4.280B
US$ 77.35
1.85 2.45
827,081
54.83M
US$ 4.240B
US$ 21.28
-0.14 -0.65
1.54M
184.69M
US$ 3.930B
US$ 198.41
3.82 1.96
216,046
19.68M
US$ 3.900B
US$ 33.90
0.22 0.65
1.61M
113.39M
US$ 3.840B
US$ 64.13
-0.59 -0.91
908,392
57.82M
US$ 3.710B
US$ 24.85
-0.13 -0.52
1.37M
146.08M
US$ 3.630B
US$ 70.28
1.24 1.80
533,421
51.68M
US$ 3.630B
US$ 46.99
0.00 0.00
0
75.35M
US$ 3.540B
US$ 90.44
2.89 3.30
314,691
37.75M
US$ 3.410B
US$ 27.78
-0.56 -1.98
1.31M
122.49M
US$ 3.400B
US$ 47.69
-0.84 -1.73
980,070
70.99M
US$ 3.390B
US$ 10.89
-0.11 -1.00
3.74M
308.53M
US$ 3.360B
US$ 43.23
0.21 0.49
774,992
77.28M
US$ 3.340B
US$ 42.04
-0.17 -0.40
586,233
79.05M
US$ 3.320B
US$ 77.48
-0.29 -0.37
348,279
42.45M
US$ 3.290B
US$ 32.84
-0.37 -1.11
1.13M
96.48M
US$ 3.170B
US$ 24.48
-0.72 -2.86
3.92M
126.53M
US$ 3.100B
US$ 34.49
0.60 1.77
1.04M
89.47M
US$ 3.090B
US$ 8.99
0.47 5.52
7.37M
341.83M
US$ 3.070B
US$ 38.00
0.61 1.63
569,273
80.67M
US$ 3.070B
US$ 31.60
-0.53 -1.65
986,178
95.37M
US$ 3.010B
US$ 18.55
-0.35 -1.85
1.35M
161.81M
US$ 3.000B
US$ 33.67
-0.36 -1.06
571,406
87.00M
US$ 2.930B
US$ 37.00
-0.02 -0.05
958,781
79.14M
US$ 2.930B
US$ 33.26
-0.47 -1.39
672,909
87.67M
US$ 2.920B
US$ 23.67
-0.33 -1.38
994,578
122.91M
US$ 2.910B
US$ 15.54
-0.80 -4.90
4.68M
185.76M
US$ 2.890B
US$ 12.98
-0.74 -5.39
3.87M
213.05M
US$ 2.770B
US$ 21.99
-0.29 -1.30
1.14M
123.73M
US$ 2.720B
US$ 26.05
0.45 1.76
1.06M
101.47M
US$ 2.640B
US$ 16.77
-0.04 -0.24
794,267
156.16M
US$ 2.620B
US$ 33.47
0.41 1.24
477,676
77.59M
US$ 2.600B
US$ 48.38
-0.88 -1.79
645,953
53.71M
US$ 2.600B
US$ 16.50
0.38 2.36
3.98M
152.67M
US$ 2.520B
US$ 30.81
-1.79 -5.49
2.30M
80.16M
US$ 2.470B
US$ 18.60
-0.10 -0.53
79,401
128.29M
US$ 2.390B
US$ 21.15
-1.16 -5.20
2.48M
105.87M
US$ 2.240B
US$ 14.89
0.00 0.00
0
148.49M
US$ 2.210B
US$ 37.47
-1.31 -3.38
710,459
57.60M
US$ 2.160B
US$ 20.34
-0.80 -3.78
2.02M
104.79M
US$ 2.130B
US$ 15.91
0.12 0.76
773,163
131.84M
US$ 2.100B
US$ 31.63
0.10 0.32
46,538
65.90M
US$ 2.080B
US$ 59.98
0.00 0.00
0
34.44M
US$ 2.070B
US$ 2.09
-0.02 -0.95
25.12M
984.97M
US$ 2.060B
US$ 26.40
0.81 3.17
350,921
74.84M
US$ 1.980B
US$ 17.18
-0.04 -0.23
3.80M
110.59M
US$ 1.900B
US$ 21.89
0.00 0.00
873,882
85.15M
US$ 1.860B
US$ 19.95
0.17 0.86
6.63M
91.71M
US$ 1.830B
US$ 5.97
0.00 0.00
4.06M
307.07M
US$ 1.830B
US$ 18.01
-0.20 -1.10
1.59M
101.37M
US$ 1.830B
US$ 36.16
-0.24 -0.66
570,480
50.57M
US$ 1.830B
US$ 36.00
0.18 0.50
122,329
50.53M
US$ 1.820B
US$ 31.93
-0.93 -2.83
665,754
57.12M
US$ 1.820B
US$ 41.75
0.32 0.77
459,282
42.88M
US$ 1.790B
US$ 20.23
-0.15 -0.74
833,407
86.91M
US$ 1.760B
US$ 25.29
-0.48 -1.86
356,015
66.45M
US$ 1.680B
US$ 29.86
1.53 5.40
652,440
54.04M
US$ 1.610B
US$ 24.02
-0.07 -0.29
124,728
64.96M
US$ 1.560B
US$ 12.19
0.08 0.66
1.32M
128.23M
US$ 1.560B
US$ 7.29
0.16 2.24
5.00M
210.54M
US$ 1.530B
US$ 16.61
0.42 2.59
2.57M
92.40M
US$ 1.530B
US$ 20.07
0.02 0.10
1.11M
74.77M
US$ 1.500B
US$ 23.95
0.92 3.99
3.19M
62.29M
US$ 1.490B
US$ 5.45
0.00 0.00
1.88M
273.92M
US$ 1.490B
US$ 4.17
0.19 4.77
7.84M
353.82M
US$ 1.480B
US$ 11.13
0.26 2.39
2.98M
132.69M
US$ 1.480B
US$ 4.73
-0.27 -5.40
1.46M
311.60M
US$ 1.470B
US$ 24.73
-0.72 -2.83
1.04M
58.31M
US$ 1.440B
US$ 3.91
-0.15 -3.69
1.64M
363.21M
US$ 1.420B
US$ 26.19
0.04 0.15
1.12M
54.40M
US$ 1.420B
US$ 17.06
0.40 2.40
1.48M
82.79M
US$ 1.410B
US$ 8.13
0.10 1.25
1.47M
173.32M
US$ 1.410B
US$ 29.64
0.96 3.35
276,989
47.66M
US$ 1.410B
US$ 26.38
-0.59 -2.19
735,096
53.05M
US$ 1.400B
US$ 5.68
-0.11 -1.90
2.63M
242.97M
US$ 1.380B
US$ 47.53
1.84 4.03
394,189
27.69M
US$ 1.320B
US$ 11.92
0.05 0.42
1.39M
109.82M
US$ 1.310B
US$ 28.67
0.98 3.54
1.02M
44.90M
US$ 1.290B
US$ 10.87
0.08 0.74
1.27M
117.42M
US$ 1.280B
US$ 9.57
-0.35 -3.53
341,307
134.06M
US$ 1.280B
US$ 85.32
2.42 2.92
143,046
14.54M
US$ 1.240B
US$ 6.06
-0.05 -0.82
3.35M
203.47M
US$ 1.230B
US$ 47.98
0.00 0.00
0
25.69M
US$ 1.230B
US$ 22.99
0.39 1.73
475,645
53.37M
US$ 1.230B
US$ 27.54
0.99 3.73
243,927
44.77M
US$ 1.230B
US$ 12.54
0.41 3.38
5.49M
97.22M
US$ 1.220B
US$ 4.50
-0.28 -5.86
2.68M
266.37M
US$ 1.200B
US$ 16.28
0.92 5.99
3.35M
71.14M
US$ 1.160B
US$ 7.01
0.01 0.14
1.98M
165.92M
US$ 1.160B
US$ 16.30
-0.31 -1.87
12,351
69.67M
US$ 1.140B
US$ 8.46
-0.32 -3.64
3.70M
134.68M
US$ 1.140B
US$ 19.48
-0.04 -0.20
246,737
57.81M
US$ 1.130B
US$ 15.69
-0.11 -0.70
497,733
71.41M
US$ 1.120B
US$ 6.68
0.15 2.30
4.89M
162.50M
US$ 1.090B
US$ 40.00
0.00 0.00
0
27.02M
US$ 1.080B
US$ 11.06
0.48 4.54
4.30M
97.21M
US$ 1.080B
US$ 22.10
0.66 3.08
23,050
48.22M
US$ 1.070B
US$ 3.53
0.18 5.37
11.06M
299.34M
US$ 1.060B
US$ 15.83
-0.92 -5.49
2.55M
65.12M
US$ 1.030B
US$ 8.88
0.09 1.02
4.73M
115.83M
US$ 1.030B
US$ 9.97
1.21 13.81
7.85M
102.68M
US$ 1.020B
US$ 3.60
-0.04 -1.10
1.84M
283.71M
US$ 1.020B
US$ 21.72
-0.90 -3.98
872,847
46.81M
US$ 1.020B
US$ 15.55
0.00 0.00
0
64.53M
US$ 1.000B
US$ 11.13
0.00 0.00
0
89.31M
US$ 994.020M
US$ 16.68
0.68 4.25
676,571
59.35M
US$ 989.960M
US$ 2.45
-0.07 -2.70
11.94M
396.97M
US$ 973.370M
US$ 9.82
-0.25 -2.48
860,654
98.85M
US$ 970.710M
US$ 17.64
-0.34 -1.89
407,294
54.78M
US$ 966.320M
US$ 4.28
0.15 3.63
2.02M
225.17M
US$ 963.730M
US$ 34.04
0.86 2.59
354,550
27.71M
US$ 943.250M
US$ 11.93
0.48 4.19
4.50M
78.79M
US$ 939.960M
US$ 13.26
-0.69 -4.95
1.57M
70.85M
US$ 939.470M
US$ 9.50
0.00 0.00
0
97.47M
US$ 925.960M
US$ 18.18
0.27 1.51
403,449
50.67M
US$ 921.180M
US$ 3.80
0.15 4.11
4.78M
237.07M
US$ 900.870M
US$ 44.00
-1.43 -3.15
1.63M
20.34M
US$ 894.960M
US$ 21.17
-1.07 -4.81
1.02M
41.28M
US$ 873.900M
US$ 4.54
-0.10 -2.16
568,753
192.32M
US$ 873.130M
US$ 21.52
-1.03 -4.57
1.50M
40.13M
US$ 863.600M
US$ 9.85
-0.33 -3.24
3.25M
87.02M
US$ 857.150M
US$ 1.34
-0.06 -4.29
4.36M
638.36M
US$ 855.400M
US$ 14.04
-0.06 -0.43
9.59M
60.15M
US$ 844.510M
US$ 5.93
-0.21 -3.42
2.59M
139.13M
US$ 825.040M
US$ 12.16
0.08 0.66
1.98M
65.97M
US$ 802.200M
US$ 12.49
0.00 0.00
0
63.96M
US$ 798.860M
US$ 4.18
-0.21 -4.68
187,849
191.02M
US$ 797.510M
US$ 3.43
-0.14 -3.92
6.68M
231.46M
US$ 793.910M
US$ 12.72
0.03 0.24
177,263
62.03M
US$ 789.020M
US$ 8.04
-0.18 -2.19
1.35M
97.39M
US$ 783.020M
US$ 9.69
0.03 0.31
1.17M
78.44M
US$ 760.080M
US$ 15.00
0.15 1.01
1.01M
50.55M
US$ 758.250M
US$ 41.77
-0.17 -0.41
348,402
18.15M
US$ 758.130M
US$ 9.96
0.85 9.33
2.22M
72.99M
US$ 726.980M
US$ 11.28
-0.44 -3.75
975,870
64.22M
US$ 724.400M
US$ 4.83
-0.07 -1.43
5.09M
149.06M
US$ 719.960M
US$ 17.16
0.00 0.00
0
41.89M
US$ 718.830M
US$ 5.81
0.18 3.20
2.04M
122.00M
US$ 708.820M
US$ 7.35
-0.06 -0.81
65,743
96.33M
US$ 708.030M
US$ 7.93
0.18 2.33
1.08M
88.80M
US$ 703.740M
US$ 8.14
-0.10 -1.21
8,046
86.38M
US$ 703.130M
US$ 32.38
0.27 0.84
44,310
21.24M
US$ 687.750M
US$ 13.51
0.34 2.58
614,161
50.62M
US$ 683.880M
US$ 3.95
-0.16 -3.99
15.74M
169.44M
US$ 668.610M
US$ 3.62
-0.12 -3.21
5.42M
180.51M
US$ 653.450M
US$ 9.16
0.33 3.74
868,267
70.90M
US$ 649.440M
US$ 7.96
-0.15 -1.85
507,356
80.49M
US$ 640.700M
US$ 20.13
-0.70 -3.36
530,660
30.47M
US$ 613.360M
US$ 7.83
0.00 0.00
0
76.38M
US$ 598.060M
US$ 9.98
0.39 4.07
1.63M
59.08M
US$ 589.620M
US$ 7.75
-0.21 -2.64
1.84M
75.32M
US$ 583.730M
US$ 3.41
0.00 0.00
0
171.00M
US$ 583.110M
US$ 7.64
-0.20 -2.55
1.41M
74.68M
US$ 570.560M
US$ 8.16
0.00 0.00
0
69.23M
US$ 564.920M
US$ 78.88
-9.20 -10.45
241,080
7.09M
US$ 559.260M
US$ 7.74
0.05 0.65
1.02M
71.36M
US$ 552.330M
US$ 8.68
0.00 0.00
0
62.78M
US$ 544.930M
US$ 4.64
0.00 0.00
0
115.27M
US$ 534.850M
US$ 17.07
0.70 4.28
845,634
31.29M
US$ 534.120M
US$ 2.29
0.01 0.44
4.96M
233.12M
US$ 533.840M
US$ 5.05
-0.04 -0.79
3.34M
104.34M
US$ 526.920M
US$ 19.45
1.26 6.93
711,138
26.97M
US$ 524.570M
US$ 9.01
0.15 1.69
3.18M
56.96M
US$ 513.210M
US$ 3.41
0.02 0.59
4.10M
150.37M
US$ 512.760M
US$ 32.35
-0.23 -0.71
149,780
15.82M
US$ 511.780M
US$ 3.52
0.06 1.73
1.07M
145.02M
US$ 510.470M
US$ 9.38
-0.05 -0.53
614,276
53.83M
US$ 504.930M
US$ 8.69
-0.52 -5.65
2.07M
57.14M
US$ 496.550M
US$ 3.90
0.23 6.27
1.99M
123.88M
US$ 483.130M
C$ 6.16
0.16 2.67
197,748
78.34M
C$ 482.570M
US$ 8.10
-0.02 -0.25
486,429
56.30M
US$ 456.030M
US$ 6.31
0.13 2.10
210,159
71.61M
US$ 451.860M
US$ 1.44
0.03 2.13
14.99M
312.32M
US$ 449.740M
US$ 10.15
0.00 0.00
0
44.21M
US$ 448.730M
US$ 12.38
0.08 0.65
114,815
35.86M
US$ 443.950M
US$ 1.67
0.05 3.09
7.65M
265.37M
US$ 443.170M
US$ 65.99
-1.71 -2.53
132,795
6.68M
US$ 440.810M
C$ 8.70
0.15 1.75
32,543
50.65M
C$ 440.650M
US$ 8.31
0.10 1.22
1.85M
52.08M
US$ 432.780M
US$ 16.02
0.20 1.26
125,978
26.82M
US$ 429.660M
US$ 1.18
0.03 2.61
5.85M
363.40M
US$ 428.810M
US$ 5.01
0.20 4.16
126,505
85.26M
US$ 427.150M
US$ 14.53
0.28 1.96
203,029
28.85M
US$ 419.190M
US$ 10.96
-0.26 -2.32
121,865
38.22M
US$ 418.890M
US$ 1.57
0.01 0.64
3.93M
266.14M
US$ 417.840M
US$ 2.15
-0.04 -1.83
3.45M
192.09M
US$ 412.990M
US$ 5.30
-0.08 -1.49
1.21M
77.91M
US$ 412.920M
US$ 17.03
0.53 3.21
906
24.17M
US$ 411.590M
US$ 1.75
-0.02 -1.13
1.15M
230.33M
US$ 403.080M
US$ 8.24
0.00 0.00
1.01M
48.52M
US$ 399.800M
US$ 6.16
-0.32 -4.94
356,224
64.47M
US$ 397.140M
US$ 6.70
-0.12 -1.76
1.90M
59.10M
US$ 395.970M
US$ 8.60
0.00 0.00
0
45.44M
US$ 390.780M
US$ 2.62
-0.02 -0.76
204,030
147.19M
US$ 385.640M
US$ 11.38
0.63 5.86
374,433
33.86M
US$ 385.330M
US$ 3.65
0.00 0.00
0
104.39M
US$ 381.020M
US$ 0.25
0.005 2.08
1.11M
1.54B
US$ 377.300M
US$ 7.15
0.00 0.00
0
52.76M
US$ 377.230M
US$ 8.05
0.00 0.00
0
46.67M
US$ 375.690M
US$ 2.95
-0.55 -15.71
1.22M
126.01M
US$ 371.730M
US$ 4.26
0.00 0.00
0
86.32M
US$ 367.720M
US$ 5.78
-0.07 -1.20
143,391
63.50M
US$ 367.030M
US$ 5.67
0.17 3.09
785,438
64.57M
US$ 366.110M
US$ 28.74
3.99 16.12
381,347
12.53M
US$ 360.110M
US$ 5.20
-0.07 -1.33
390,534
68.75M
US$ 357.500M
US$ 2.48
0.13 5.53
4.24M
141.55M
US$ 351.040M
US$ 3.23
-0.04 -1.22
1.26M
108.22M
US$ 349.550M
US$ 3.89
-0.03 -0.77
2.84M
89.35M
US$ 347.570M
US$ 18.91
-0.34 -1.77
659,591
18.13M
US$ 342.840M
US$ 6.77
-0.18 -2.59
315,558
49.93M
US$ 338.030M
US$ 6.77
0.02 0.30
714,891
49.89M
US$ 337.760M
US$ 2.36
0.25 11.85
10.72M
142.44M
US$ 336.160M
US$ 3.08
0.05 1.65
487,132
108.35M
US$ 333.720M
US$ 3.66
0.16 4.57
458,068
87.44M
US$ 320.030M
US$ 2.30
0.18 8.49
15.22M
137.04M
US$ 315.190M
US$ 1.39
-0.03 -2.11
2.63M
224.73M
US$ 312.370M
US$ 24.90
-0.36 -1.43
45,942
12.38M
US$ 308.260M
US$ 7.00
0.09 1.30
9.77M
43.80M
US$ 306.600M
US$ 1.92
0.00 0.00
13.81M
159.13M
US$ 305.530M
US$ 4.15
0.14 3.49
828,406
73.33M
US$ 304.320M
US$ 5.54
0.04 0.73
937,731
54.90M
US$ 304.150M
US$ 5.01
-0.24 -4.57
1.33M
60.16M
US$ 301.400M
US$ 4.16
0.19 4.79
31,249
72.33M
US$ 300.890M
US$ 19.28
0.10 0.52
182,743
15.49M
US$ 298.650M
US$ 2.95
0.01 0.34
457,673
100.60M
US$ 296.770M
US$ 3.43
-0.03 -0.87
2.41M
85.59M
US$ 293.570M
US$ 1.72
-0.05 -2.82
788,375
169.94M
US$ 292.300M
US$ 2.01
-0.06 -2.90
772,733
143.96M
US$ 289.360M
US$ 13.83
0.10 0.73
47,208
20.79M
US$ 287.530M
US$ 5.62
0.04 0.72
181,151
50.39M
US$ 283.190M
US$ 5.00
0.36 7.76
315,838
56.55M
US$ 282.750M
US$ 12.80
-1.46 -10.24
2.59M
21.91M
US$ 280.450M
US$ 4.27
-0.01 -0.23
183,511
65.02M
US$ 277.640M
US$ 5.18
-0.17 -3.18
850,656
51.63M
US$ 267.440M
US$ 4.92
0.07 1.44
718,013
54.19M
US$ 266.610M
US$ 5.00
0.00 0.00
0
53.23M
US$ 266.150M
US$ 11.39
-0.09 -0.78
537,196
23.10M
US$ 263.110M
US$ 7.58
0.04 0.53
54,761
34.15M
US$ 258.860M
US$ 4.00
0.00 0.00
0
64.56M
US$ 258.240M
US$ 1.67
-0.02 -1.18
1.44M
149.00M
US$ 248.830M
US$ 1.94
0.08 4.30
378,632
126.31M
US$ 245.040M
US$ 4.34
0.04 0.93
84,880
56.46M
US$ 245.040M
US$ 3.13
-0.05 -1.57
150,822
78.13M
US$ 244.550M
US$ 4.85
0.00 0.00
0
50.00M
US$ 242.500M
US$ 18.84
0.19 1.02
36,424
12.82M
US$ 241.530M
US$ 1.29
0.02 1.57
10.82M
183.36M
US$ 236.530M
US$ 2.41
0.08 3.43
3.51M
96.27M
US$ 232.010M
US$ 4.34
0.11 2.60
1.11M
53.23M
US$ 231.020M
US$ 2.35
-0.02 -0.84
2.54M
97.62M
US$ 229.410M
US$ 2.27
0.00 0.00
0
100.95M
US$ 229.160M
US$ 4.12
-0.14 -3.29
299,607
55.60M
US$ 229.070M
US$ 2.12
-0.01 -0.47
469,761
105.35M
US$ 223.340M
US$ 18.51
0.52 2.89
286,536
11.78M
US$ 218.050M
US$ 4.47
0.00 0.00
0
48.36M
US$ 216.170M
US$ 3.78
-2.90 -43.41
4.85M
56.64M
US$ 214.100M
US$ 1.11
0.04 3.74
25.30M
187.27M
US$ 207.870M
US$ 7.98
0.40 5.28
51,059
25.61M
US$ 204.370M
US$ 1.67
0.08 5.03
660,082
121.27M
US$ 202.520M
US$ 5.40
-0.26 -4.59
47,491
36.41M
US$ 196.610M
US$ 0.83
-0.0019 -0.23
2.50M
236.29M
US$ 196.590M
US$ 3.48
-0.24 -6.45
1.56M
55.68M
US$ 193.770M
US$ 7.36
-0.07 -0.94
171,486
26.00M
US$ 191.360M
US$ 6.06
-0.21 -3.35
993,475
31.00M
US$ 187.860M
US$ 2.96
0.07 2.42
140,791
63.28M
US$ 187.310M
US$ 21.49
0.64 3.07
254,071
8.57M
US$ 184.170M
US$ 6.43
-0.09 -1.38
387,044
28.41M
US$ 182.680M
US$ 2.09
-0.06 -2.60
14.34M
85.17M
US$ 178.350M
US$ 1.85
-0.16 -7.96
8.22M
92.73M
US$ 171.550M
US$ 1.44
-0.02 -1.37
352,612
118.82M
US$ 171.100M
US$ 2.50
0.09 3.73
1.59M
67.36M
US$ 168.400M
US$ 12.10
1.36 12.66
631,875
13.85M
US$ 167.580M
US$ 1.36
0.01 0.74
1.18M
120.87M
US$ 164.380M
US$ 7.02
0.16 2.33
20,466
23.24M
US$ 163.140M
US$ 2.37
-0.23 -8.85
4.40M
68.70M
US$ 162.820M
US$ 1.76
-0.05 -2.76
54,713
92.18M
US$ 162.240M
C$ 2.11
0.05 2.43
600
76.38M
C$ 161.160M
US$ 4.28
0.05 1.18
2,210
37.40M
US$ 160.070M
US$ 4.19
0.04 0.96
67,190
38.05M
US$ 159.430M
US$ 2.61
-0.19 -6.79
61,817
59.99M
US$ 156.570M
US$ 1.63
0.01 0.62
2.67M
93.47M
US$ 152.360M
US$ 1.39
0.04 2.96
5.61M
109.15M
US$ 151.720M
US$ 1.52
0.10 7.04
3.74M
97.55M
US$ 148.280M
US$ 1.64
0.03 1.86
4.67M
90.32M
US$ 148.120M
US$ 29.10
0.04 0.14
33,825
5.00M
US$ 145.500M
US$ 21.99
0.00 0.00
0
6.60M
US$ 145.130M
US$ 2.54
-0.05 -1.93
772,532
56.97M
US$ 144.700M
US$ 0.43
-0.0082 -1.87
12.65M
336.49M
US$ 144.690M
US$ 1.80
0.04 2.16
355,115
80.42M
US$ 144.600M
US$ 8.10
-0.05 -0.61
238,286
17.55M
US$ 142.160M
US$ 1.51
0.00 0.00
557,779
93.54M
US$ 141.250M
US$ 15.28
-0.16 -1.04
38,229
9.05M
US$ 138.280M
US$ 2.86
0.01 0.35
558,152
48.31M
US$ 138.170M
US$ 7.99
0.12 1.52
110,912
17.26M
US$ 137.910M
US$ 9.55
0.12 1.27
189,349
14.42M
US$ 137.710M
US$ 34.72
0.31 0.90
8,835
3.94M
US$ 136.800M
US$ 1.50
0.04 2.74
839,601
88.27M
US$ 132.400M
US$ 2.29
-0.02 -0.87
588,048
56.34M
US$ 129.020M
US$ 2.30
0.04 1.77
18,461
55.90M
US$ 128.570M
US$ 2.12
0.07 3.41
253,137
60.57M
US$ 128.410M
US$ 6.21
-0.92 -12.90
1.52M
20.16M
US$ 125.190M
US$ 1.76
-0.01 -0.56
2.57M
71.03M
US$ 125.010M
C$ 0.67
-0.01 -1.47
246,150
185.51M
C$ 124.290M
US$ 17.23
0.05 0.29
27,410
7.21M
US$ 124.230M
US$ 1.05
0.00 0.00
4.42M
115.35M
US$ 121.120M
US$ 3.51
-0.08 -2.23
307,867
34.01M
US$ 119.380M
US$ 42.75
2.16 5.32
4,368
2.79M
US$ 119.270M
US$ 2.98
-0.05 -1.65
76,848
39.80M
US$ 118.600M
US$ 1.57
0.00 0.00
1.90M
75.03M
US$ 117.800M
US$ 5.40
-0.05 -0.92
413,318
21.49M
US$ 116.050M
US$ 4.68
0.36 8.33
726,000
24.54M
US$ 114.850M
US$ 0.67
0.001 0.15
48.57M
166.51M
US$ 111.230M
US$ 5.30
-0.30 -5.36
349,198
20.92M
US$ 110.880M
US$ 6.50
0.50 8.33
159,668
17.05M
US$ 110.820M
US$ 5.05
-0.30 -5.61
491,008
21.74M
US$ 109.790M
US$ 4.52
-0.25 -5.24
147,558
24.07M
US$ 108.800M
US$ 1.01
0.00 0.00
2.41M
107.61M
US$ 108.690M
US$ 9.98
0.87 9.55
191,019
10.73M
US$ 107.090M
US$ 3.24
-0.03 -0.92
449,999
32.92M
US$ 106.660M
US$ 1.15
0.03 2.68
5.91M
91.88M
US$ 105.660M
US$ 1.69
-1.67 -49.70
19.68M
62.26M
US$ 105.220M
US$ 2.09
0.00 0.00
0
50.13M
US$ 104.770M
US$ 2.15
0.15 7.50
3,995
48.08M
US$ 103.370M
US$ 3.33
-0.08 -2.35
410,708
31.04M
US$ 103.360M
US$ 1.71
0.00 0.00
0
60.18M
US$ 102.910M
US$ 1.42
0.08 5.97
6.35M
72.25M
US$ 102.600M
US$ 7.22
0.90 14.24
36,116
13.79M
US$ 99.560M
US$ 1.57
-0.04 -2.48
10.63M
63.26M
US$ 99.320M
US$ 3.67
0.05 1.38
600,999
26.50M
US$ 97.260M
US$ 4.36
0.00 0.00
0
22.08M
US$ 96.270M
US$ 1.92
-0.03 -1.54
182,776
50.02M
US$ 96.040M
US$ 1.35
0.00 0.00
1.27M
70.70M
US$ 95.440M
US$ 1.34
-0.14 -9.46
7.69M
71.21M
US$ 95.420M
US$ 1.82
-0.01 -0.55
271,761
51.76M
US$ 94.200M
US$ 2.15
-0.04 -1.83
566,351
42.99M
US$ 92.430M
US$ 2.07
-0.20 -8.81
16.23M
44.42M
US$ 91.950M
US$ 0.70
-0.01 -1.41
583,528
129.17M
US$ 90.940M
US$ 2.21
-0.15 -6.36
122,916
41.08M
US$ 90.790M
US$ 1.97
-0.01 -0.51
22,034
45.86M
US$ 90.340M
US$ 1.93
0.00 0.00
0
46.15M
US$ 89.070M
US$ 0.37
0.0001 0.03
63,479
240.06M
US$ 88.580M
US$ 2.25
-1.80 -44.44
15.05M
38.46M
US$ 86.540M
US$ 1.83
-0.03 -1.61
17,948
47.13M
US$ 86.250M
C$ 1.02
-0.06 -5.56
42,136
83.41M
C$ 85.080M
C$ 1.26
-0.02 -1.56
53,400
66.93M
C$ 84.330M
US$ 76.77
0.93 1.23
21,735
1.07M
US$ 82.140M
US$ 12.82
1.03 8.74
472,615
6.24M
US$ 80.000M
US$ 2.22
-0.14 -5.93
2.20M
35.04M
US$ 77.790M
US$ 2.68
0.00 0.00
0
28.91M
US$ 77.480M
US$ 2.53
0.10 4.12
55,715
30.49M
US$ 77.140M
US$ 8.11
0.06 0.75
274,953
9.49M
US$ 76.960M
US$ 1.87
-0.03 -1.58
87,473
41.12M
US$ 76.890M
US$ 1.41
-0.04 -2.76
226,558
54.22M
US$ 76.450M
US$ 8.93
-0.20 -2.19
59,472
8.52M
US$ 76.080M
US$ 0.55
-0.03 -5.34
5.89M
137.43M
US$ 75.450M
US$ 11.10
0.09 0.82
44,143
6.78M
US$ 75.220M
US$ 1.21
-0.01 -0.82
1.75M
61.45M
US$ 74.350M
US$ 3.00
0.00 0.00
0
24.68M
US$ 74.040M
US$ 7.82
-0.09 -1.14
172,445
9.42M
US$ 73.660M
US$ 7.90
-0.09 -1.13
34,697
9.25M
US$ 73.080M
US$ 0.47
-0.0003 -0.06
5.99M
153.26M
US$ 72.030M
US$ 1.06
0.05 4.95
2.70M
67.75M
US$ 71.820M
US$ 2.26
-0.05 -2.16
936,747
31.56M
US$ 71.330M
US$ 1.45
-0.02 -1.36
50,762
49.15M
US$ 71.270M
US$ 4.90
-0.12 -2.39
49,514
14.41M
US$ 70.610M
US$ 1.87
0.04 2.19
17,220
37.61M
US$ 70.330M
US$ 0.70
-0.0075 -1.06
2.98M
97.99M
US$ 68.890M
US$ 0.57
-0.01 -2.24
11.72M
120.28M
US$ 68.200M
US$ 5.69
0.00 0.00
0
11.82M
US$ 67.260M
US$ 0.58
-0.04 -5.86
14.50M
115.06M
US$ 66.730M
US$ 0.76
0.10 14.32
15.43M
87.41M
US$ 66.690M
US$ 1.08
-0.02 -1.82
1.62M
60.89M
US$ 65.760M
US$ 1.23
0.10 8.85
575,829
53.21M
US$ 65.450M
US$ 3.92
-0.01 -0.25
49,597
16.63M
US$ 65.190M
C$ 0.69
0.00 0.00
14,151
90.68M
C$ 62.570M
US$ 6.04
-0.48 -7.36
65,842
10.33M
US$ 62.390M
US$ 1.66
0.02 1.22
215,682
37.55M
US$ 62.330M
US$ 2.17
-0.11 -4.82
948,982
28.10M
US$ 60.980M
US$ 1.58
0.02 1.28
1.07M
37.77M
US$ 59.680M
US$ 1.60
0.06 3.90
326,785
35.21M
US$ 56.340M
US$ 6.14
0.05 0.82
10,523
9.05M
US$ 55.570M
US$ 10.37
-0.26 -2.45
46,986
5.35M
US$ 55.480M
US$ 4.53
0.13 2.95
8,160
12.16M
US$ 55.080M
US$ 3.03
0.11 3.77
16,469
18.13M
US$ 54.930M
US$ 11.53
-0.18 -1.54
7,873
4.69M
US$ 54.080M
US$ 0.88
0.00 0.00
0
60.97M
US$ 53.650M
C$ 0.47
0.00 0.00
0
113.01M
C$ 53.110M
US$ 1.86
0.14 8.14
2.88M
27.98M
US$ 52.040M
US$ 1.59
-0.07 -4.22
167,409
31.20M
US$ 49.610M
US$ 2.04
-0.01 -0.49
71,079
24.30M
US$ 49.570M
US$ 9.81
0.00 0.00
0
5.02M
US$ 49.250M
C$ 0.07
0.00 0.00
5,000
701.73M
C$ 49.120M
US$ 0.93
0.0024 0.26
2.23M
52.47M
US$ 48.850M
US$ 4.97
0.00 0.00
0
9.79M
US$ 48.660M
US$ 1.55
-0.10 -6.06
3,670
31.24M
US$ 48.420M
US$ 1.82
-0.01 -0.55
252,614
26.59M
US$ 48.390M
US$ 5.75
-0.11 -1.88
101,825
8.34M
US$ 47.960M
US$ 0.88
0.01 1.17
836,979
54.72M
US$ 47.930M
C$ 1.73
-0.01 -0.57
14,544
27.42M
C$ 47.440M
US$ 3.35
0.00 0.00
23,355
14.13M
US$ 47.340M
US$ 1.37
0.02 1.48
395,300
34.38M
US$ 47.100M
US$ 1.14
0.00 0.00
0
41.10M
US$ 46.850M
US$ 0.79
0.0095 1.21
1.86M
58.79M
US$ 46.560M
US$ 1.27
0.00 0.00
0
36.59M
US$ 46.470M
US$ 6.32
0.06 0.96
35,421
7.32M
US$ 46.260M
US$ 2.73
0.00 0.00
0
16.84M
US$ 45.970M
US$ 1.74
0.00 0.00
0
26.31M
US$ 45.780M
US$ 0.62
-0.01 -2.03
5.20M
71.95M
US$ 44.750M
US$ 1.20
0.05 4.35
340,523
37.03M
US$ 44.440M
US$ 5.50
-0.11 -1.96
74,631
7.99M
US$ 43.940M
US$ 3.41
-0.04 -1.16
29
12.59M
US$ 42.930M
US$ 1.88
-0.01 -0.53
2.08M
22.49M
US$ 42.280M
C$ 0.13
0.002 1.60
67,040
328.69M
C$ 41.740M
US$ 26.00
-0.33 -1.25
29,283
1.59M
US$ 41.340M
US$ 1.83
0.03 1.67
304,306
21.87M
US$ 40.020M
US$ 3.11
0.17 5.78
27,755
12.86M
US$ 39.990M
US$ 0.09
-0.004 -4.26
42,000
442.60M
US$ 39.830M
US$ 6.09
0.28 4.82
91,069
6.37M
US$ 38.790M
C$ 0.69
-0.08 -10.39
308,685
54.73M
C$ 37.760M
US$ 4.34
0.00 0.00
0
8.65M
US$ 37.540M
US$ 5.45
0.09 1.68
41,022
6.74M
US$ 36.730M
US$ 9.55
0.55 6.11
2,300
3.81M
US$ 36.390M
US$ 10.70
0.19 1.81
13,842
3.39M
US$ 36.270M
US$ 3.24
0.05 1.57
67,979
11.18M
US$ 36.220M
US$ 1.25
-0.05 -3.85
70,671
28.32M
US$ 35.400M
US$ 2.04
0.00 0.00
0
17.34M
US$ 35.370M
US$ 1.33
0.00 0.00
0
26.20M
US$ 34.850M
US$ 1.47
0.08 5.76
12,572
23.43M
US$ 34.440M
US$ 1.29
-0.01 -0.77
181,029
26.29M
US$ 33.910M
US$ 0.65
-0.0053 -0.82
2.83M
52.50M
US$ 33.860M
US$ 8.82
0.54 6.52
51,763
3.83M
US$ 33.780M
US$ 8.32
-0.34 -3.93
35,320
4.05M
US$ 33.700M
US$ 0.90
0.02 2.35
80,377
36.65M
US$ 32.980M
US$ 0.91
0.01 1.46
59,804
36.19M
US$ 32.930M
US$ 1.42
0.00 0.00
0
23.18M
US$ 32.920M
US$ 0.78
0.06 8.37
334,878
42.24M
US$ 32.860M
US$ 15.12
0.04 0.27
5,419
2.14M
US$ 32.360M
US$ 1.00
-0.06 -5.66
757,290
32.06M
US$ 32.060M
US$ 3.45
0.48 16.16
76,555
9.25M
US$ 31.910M
US$ 0.34
0.01 3.50
1.52M
92.87M
US$ 31.580M
C$ 0.19
0.00 0.00
0
165.94M
C$ 31.530M
US$ 0.65
-0.42 -39.53
15.00M
48.54M
US$ 31.410M
US$ 1.17
-0.05 -4.10
644,998
26.29M
US$ 30.760M
US$ 2.28
-0.10 -4.20
448,287
13.48M
US$ 30.730M
US$ 0.55
0.00 0.00
0
55.22M
US$ 30.370M
C$ 0.11
-0.005 -4.55
11,500
287.34M
C$ 30.170M
US$ 9.44
0.43 4.77
12,383
3.18M
US$ 30.020M
US$ 0.73
0.01 1.67
94,917
40.83M
US$ 29.850M
US$ 0.33
0.00 0.00
0
90.38M
US$ 29.740M
C$ 0.57
-0.01 -1.72
48,000
51.84M
C$ 29.550M
US$ 0.75
-0.11 -13.24
32.33M
39.50M
US$ 29.510M
C$ 0.21
-0.03 -12.50
339,984
138.99M
C$ 29.190M
US$ 1.27
0.00 0.00
643,662
22.39M
US$ 28.440M
US$ 2.66
-0.28 -9.63
13,535
10.66M
US$ 28.320M
US$ 3.87
0.07 1.84
16,411
6.99M
US$ 27.050M
US$ 6.70
2.56 61.84
81.02M
3.94M
US$ 26.400M
US$ 3.86
0.04 1.05
118,087
6.76M
US$ 26.090M
US$ 0.63
0.00 0.00
0
41.21M
US$ 25.840M
US$ 2.47
-0.10 -3.89
114,751
10.19M
US$ 25.170M
US$ 0.41
-0.0089 -2.12
3.17M
60.06M
US$ 24.680M
US$ 1.10
-0.05 -4.35
510,701
22.40M
US$ 24.640M
US$ 5.32
0.00 0.00
0
4.57M
US$ 24.310M
US$ 0.82
-0.01 -1.45
392,913
29.70M
US$ 24.290M
US$ 4.20
0.53 14.44
1.37M
5.55M
US$ 23.310M
US$ 1.21
-0.03 -2.42
223,468
18.00M
US$ 21.780M
US$ 0.37
0.00 0.00
0
59.25M
US$ 21.630M
US$ 3.89
0.09 2.37
73,868
5.38M
US$ 20.930M
US$ 1.14
0.01 0.88
25,560
18.06M
US$ 20.590M
US$ 2.36
0.00 0.00
0
8.62M
US$ 20.340M
US$ 0.59
-0.02 -2.50
68.84M
33.29M
US$ 19.470M
US$ 1.02
-0.02 -1.92
198,523
18.47M
US$ 18.840M
US$ 0.39
-0.0011 -0.28
1.05M
48.05M
US$ 18.640M
US$ 1.56
-0.02 -1.27
15,231
11.73M
US$ 18.300M
US$ 8.42
-0.50 -5.61
48,796
2.15M
US$ 18.100M
US$ 13.60
0.00 0.00
0
1.32M
US$ 17.950M
C$ 0.14
-0.005 -3.57
25,000
132.87M
C$ 17.940M
US$ 0.12
0.004 3.33
16.75M
144.30M
US$ 17.890M
US$ 35.07
-0.74 -2.07
192,715
505,798
US$ 17.740M
US$ 2.01
0.00 0.00
9,063
8.82M
US$ 17.730M
US$ 1.38
-0.05 -3.50
78,496
12.78M
US$ 17.640M
US$ 1.04
0.01 0.97
640,345
16.85M
US$ 17.520M
US$ 9.01
0.28 3.21
19,038
1.88M
US$ 16.940M
US$ 1.09
0.02 1.40
138,763
15.51M
US$ 16.830M
US$ 1.26
-0.02 -1.56
311,722
12.94M
US$ 16.300M
US$ 1.02
0.004 0.39
65,593
15.80M
US$ 16.180M
C$ 0.09
0.00 0.00
62,000
188.49M
C$ 16.020M
US$ 0.26
-0.01 -5.37
4.03M
61.29M
US$ 16.000M
C$ 0.06
0.00 0.00
0
258.84M
C$ 15.530M
US$ 7.37
-0.57 -7.18
125,847
2.08M
US$ 15.330M
US$ 0.69
0.0034 0.50
965,474
22.23M
US$ 15.230M
US$ 1.15
-0.02 -1.71
30,630
12.93M
US$ 14.870M
US$ 2.98
0.04 1.36
56,477
4.93M
US$ 14.690M
US$ 0.05
0.00 0.00
0
265.05M
US$ 14.550M
US$ 8.54
0.00 0.00
0
1.70M
US$ 14.520M
US$ 1.01
0.04 4.12
102,777
13.80M
US$ 13.940M
US$ 1.00
0.01 1.06
46,622
13.78M
US$ 13.780M
US$ 1.30
0.03 1.97
82,144
10.61M
US$ 13.740M
US$ 3.72
-0.33 -8.15
12,708
3.65M
US$ 13.580M
US$ 1.13
0.02 1.80
81,767
11.70M
US$ 13.220M
US$ 0.83
-0.01 -1.20
8,208
15.49M
US$ 12.890M
US$ 2.96
-0.02 -0.67
17,212
4.35M
US$ 12.880M
US$ 1.23
0.00 0.00
2.57M
10.09M
US$ 12.410M
US$ 0.22
0.00 0.00
0
55.66M
US$ 11.990M
US$ 1.92
-0.16 -7.69
271,892
6.16M
US$ 11.830M
C$ 0.02
-0.005 -20.00
606,500
586.81M
C$ 11.740M
US$ 3.79
-0.08 -2.07
19,661
3.07M
US$ 11.640M
US$ 13.82
-0.78 -5.34
51,177
838,977
US$ 11.590M
US$ 2.71
-0.03 -1.09
25,372
4.24M
US$ 11.490M
US$ 9.12
0.68 8.06
13,073
1.26M
US$ 11.490M
US$ 1.06
-0.01 -0.93
572,085
10.76M
US$ 11.410M
US$ 0.55
-0.05 -7.55
821,746
19.85M
US$ 10.940M
US$ 1.45
0.00 0.00
56,835
7.54M
US$ 10.930M
C$ 0.10
-0.02 -13.04
306,756
108.62M
C$ 10.860M
US$ 1.47
-0.05 -3.03
21,961
7.34M
US$ 10.820M
US$ 10.11
-0.05 -0.49
77,311
1.04M
US$ 10.510M
US$ 1.18
0.08 7.27
82,599
8.88M
US$ 10.480M
US$ 1.25
-0.15 -10.71
1.91M
7.99M
US$ 9.990M
US$ 0.78
0.05 6.38
131,219
12.85M
US$ 9.960M
C$ 0.13
0.00 0.00
0
76.57M
C$ 9.950M
US$ 5.16
4.60 821.43
39,067
1.92M
US$ 9.900M
US$ 1.26
0.03 2.44
29,488
7.85M
US$ 9.890M
US$ 2.05
0.08 4.06
19,069
4.81M
US$ 9.860M
C$ 0.11
0.00 0.00
51,500
91.02M
C$ 9.560M
US$ 0.20
0.00 0.00
0
47.31M
US$ 9.520M
US$ 1.31
0.06 4.80
89,839
7.17M
US$ 9.390M
C$ 0.13
-0.20 -60.94
1,000
74.76M
C$ 9.350M
US$ 1.30
0.00 0.00
0
6.83M
US$ 8.880M
US$ 3.98
-0.02 -0.50
39,644
2.23M
US$ 8.880M
US$ 0.25
-0.0045 -1.80
384.81M
35.74M
US$ 8.790M
C$ 0.15
-0.005 -3.23
12,000
58.00M
C$ 8.700M
US$ 2.72
0.00 0.00
0
3.18M
US$ 8.650M
US$ 2.16
0.01 0.47
68,231
3.80M
US$ 8.210M
US$ 0.36
0.00 0.00
0
23.14M
US$ 8.210M
US$ 3.91
-0.23 -5.53
142,814
2.07M
US$ 8.100M
US$ 0.14
0.00 0.00
0
55.37M
US$ 7.900M
US$ 0.74
0.04 5.00
10.90M
10.64M
US$ 7.820M
US$ 2.10
0.05 2.44
32,041
3.68M
US$ 7.730M
US$ 0.94
0.0023 0.24
36,158
8.08M
US$ 7.630M
US$ 2.43
-0.14 -5.45
112,014
3.13M
US$ 7.610M
C$ 0.05
0.00 0.00
11,000
151.90M
C$ 7.600M
US$ 1.14
0.04 3.73
92,919
6.35M
US$ 7.250M
US$ 3.45
-0.05 -1.43
24,995
2.09M
US$ 7.210M
US$ 7.85
-0.61 -7.21
22,906
916,968
US$ 7.200M
US$ 0.24
-0.01 -4.00
7.60M
29.71M
US$ 7.130M
US$ 1.06
-0.03 -2.75
88,719
6.45M
US$ 6.840M
US$ 3.47
0.04 1.17
22,492
1.91M
US$ 6.630M
US$ 0.73
-0.01 -1.78
246,640
9.03M
US$ 6.590M
US$ 3.72
-0.12 -3.12
11,872
1.77M
US$ 6.580M
US$ 0.59
0.04 6.63
2,762
11.03M
US$ 6.510M
US$ 1.38
-0.04 -2.82
50,394
4.63M
US$ 6.390M
US$ 0.26
0.0018 0.69
346,018
23.99M
US$ 6.290M
US$ 0.58
-0.0093 -1.58
2.57M
10.73M
US$ 6.210M
US$ 4.61
0.00 0.00
0
1.33M
US$ 6.120M
US$ 2.84
0.00 0.00
0
2.12M
US$ 6.020M
US$ 0.20
0.00 0.00
0
30.12M
US$ 5.930M
C$ 0.04
0.005 16.67
27,000
167.35M
C$ 5.860M
US$ 0.17
-0.01 -5.67
2.57M
33.74M
US$ 5.840M
US$ 0.07
0.00 0.00
0
88.99M
US$ 5.780M
US$ 0.91
-0.0002 -0.02
57,736
6.31M
US$ 5.740M
US$ 0.84
0.02 1.84
833,428
6.80M
US$ 5.710M
US$ 2.18
0.06 2.59
69,634
2.58M
US$ 5.610M
US$ 1.47
-0.05 -3.29
19,134
3.81M
US$ 5.600M
US$ 0.94
0.00 0.00
0
5.97M
US$ 5.580M
US$ 0.90
-0.03 -3.17
76,080
5.92M
US$ 5.330M
US$ 0.02
-0.001 -5.88
46,875
332.96M
US$ 5.330M
US$ 2.82
0.00 0.00
13,900
1.83M
US$ 5.160M
US$ 0.39
-0.02 -3.99
312,149
13.32M
US$ 5.130M
US$ 0.89
-0.03 -2.87
120,267
5.48M
US$ 4.870M
US$ 0.76
0.03 4.43
29,997
6.41M
US$ 4.840M
US$ 2.06
0.04 1.98
27,227
2.29M
US$ 4.720M
US$ 0.91
0.00 0.00
0
5.17M
US$ 4.700M
US$ 0.34
0.00 0.00
0
13.54M
US$ 4.560M
US$ 1.05
0.00 0.00
0
4.25M
US$ 4.460M
C$ 0.01
0.00 0.00
0
432.32M
C$ 4.320M
US$ 0.25
-0.02 -8.63
1.66M
17.07M
US$ 4.270M
US$ 1.13
-0.06 -5.04
59,504
3.74M
US$ 4.230M
US$ 1.08
0.19 21.70
2.49M
3.84M
US$ 4.150M
US$ 0.50
0.00 0.00
0
8.21M
US$ 4.110M
US$ 0.59
0.006 1.03
5,926
6.96M
US$ 4.110M
US$ 1.13
0.00 0.00
68,484
3.63M
US$ 4.100M
US$ 0.67
0.02 2.76
482,759
5.86M
US$ 3.930M
US$ 6.68
-0.24 -3.47
9,318
574,580
US$ 3.840M
US$ 1.15
-0.02 -1.71
51,758
3.33M
US$ 3.830M
US$ 0.03
0.00 0.00
0
118.11M
US$ 3.800M
US$ 2.11
-0.03 -1.40
13,999
1.75M
US$ 3.690M
US$ 1.29
0.09 7.50
377,922
2.80M
US$ 3.610M
US$ 0.84
-0.009 -1.06
40,396
4.23M
US$ 3.550M
US$ 2.17
-0.15 -6.47
100,226
1.63M
US$ 3.540M
US$ 1.63
-0.11 -6.32
22,097
2.15M
US$ 3.500M
US$ 0.83
0.0001 0.01
26,142
4.17M
US$ 3.440M
US$ 1.69
-0.13 -7.14
146,526
2.02M
US$ 3.410M
US$ 0.29
-0.01 -3.78
327,877
10.74M
US$ 3.060M
C$ 0.03
0.00 0.00
0
121.27M
C$ 3.030M
US$ 5.06
-0.48 -8.68
185,663
596,978
US$ 3.020M
US$ 1.84
-0.07 -3.66
229,281
1.56M
US$ 2.870M
C$ 1.39
0.00 0.00
0
2.04M
C$ 2.840M
US$ 1.70
0.00 0.00
0
1.61M
US$ 2.740M
C$ 0.08
-0.005 -5.88
5,272
34.26M
C$ 2.740M
US$ 4.25
-1.21 -22.16
7.08M
619,523
US$ 2.630M
US$ 0.56
0.00 0.00
0
4.52M
US$ 2.530M
US$ 0.39
-0.02 -4.34
299,885
6.54M
US$ 2.520M
US$ 1.29
-0.08 -5.84
71,135
1.93M
US$ 2.490M
US$ 0.02
0.00 0.00
0
124.38M
US$ 2.490M
US$ 0.25
0.00 0.00
0
9.66M
US$ 2.390M
US$ 0.74
-0.11 -12.94
241,828
3.19M
US$ 2.360M
C$ 0.03
0.00 0.00
0
75.74M
C$ 2.270M
US$ 0.05
0.005 10.20
52,200
41.85M
US$ 2.260M
US$ 2.18
-0.12 -5.22
37,405
1.03M
US$ 2.250M
US$ 0.31
-0.09 -22.50
1
7.24M
US$ 2.240M
C$ 0.10
0.00 0.00
43,000
21.15M
C$ 2.120M
US$ 0.65
0.0002 0.03
12
3.18M
US$ 2.070M
US$ 0.39
0.00 0.00
0
5.23M
US$ 2.040M
US$ 0.10
0.00 0.00
0
17.21M
US$ 1.800M
US$ 0.02
-0.0005 -2.13
16,025
75.46M
US$ 1.740M
C$ 0.005
0.00 0.00
35,000
312.86M
C$ 1.560M
C$ 0.005
0.00 0.00
0
283.28M
C$ 1.420M
US$ 0.09
0.00 0.00
0
16.39M
US$ 1.390M
C$ 0.10
0.00 0.00
3,000
13.86M
C$ 1.390M
US$ 0.04
0.002 5.26
232,279
33.71M
US$ 1.350M
US$ 0.30
0.00 0.00
0
3.78M
US$ 1.130M
US$ 0.13
-0.0096 -6.69
1,220
8.10M
US$ 1.090M
US$ 0.21
-0.02 -8.74
212
4.62M
US$ 970K
US$ 0.20
0.00 0.00
0
4.44M
US$ 894K
US$ 0.07
-0.002 -2.99
86
11.62M
US$ 755K
US$ 1.27
-0.47 -26.84
1.54M
559,444
US$ 712K
US$ 0.11
0.00 0.00
0
6.58M
US$ 705K
US$ 0.02
0.00 0.00
0
29.49M
US$ 678K
US$ 0.001
-0.0003 -23.08
521,725
635.87M
US$ 636K
US$ 0.07
-0.001 -1.41
130
8.31M
US$ 582K
US$ 0.25
0.00 0.00
0
1.63M
US$ 413K
US$ 0.21
0.00 0.00
0
1.55M
US$ 326K
US$ 0.008
0.00 0.00
0
39.74M
US$ 318K
US$ 0.07
0.00 0.00
0
4.44M
US$ 289K
US$ 0.001
0.00 0.00
0
232.37M
US$ 232K
US$ 0.37
0.00 0.00
0
581,000
US$ 215K
US$ 0.16
0.00 0.00
0
1.33M
US$ 206K
US$ 0.11
0.00 0.00
0
1.24M
US$ 135K
US$ 0.02
0.00 0.00
0
4.85M
US$ 97K
US$ 0.005
0.00 0.00
0
5.23M
US$ 26K
US$ 0.02
0.00 0.00
0
1.24M
US$ 26K
US$ 0.01
0.00 0.00
0
863,788
US$ 10K
US$ 0.07
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
4.87M
US$ -
US$ 1.06
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 3.01
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 32.95
0.00 0.00
0
-
US$ -
US$ 1.20
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
1.39M
US$ -
US$ 0.00
0.00 0.00
0
125.63M
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
5.12B
US$ -
US$ 0.02
0.00 0.00
0
-
US$ -
US$ 0.001
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
261.79M
US$ -
US$ 0.40
-0.02 -4.76
1.74M
-
US$ -
C$ 2.60
0.00 0.00
0
-
C$ -
US$ 1.46
-0.02 -1.35
243,930
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -
US$ 0.00
0.00 0.00
0
-
US$ -

Latest Biotechnology Stock News


Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced underwritten public offering of 8,000,000 shares of its common stock, which includes 1,043,478 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares,... Read more


Annovis Bio Announces Open-Label Extension Study for Parkinson's Disease Patients

Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced it will begin an Open-Label... Read more


Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

Event to be held January 6th, 2026, at 10 a.m. EST BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it will host a virtual key opinion leader (KOL) event, “Understanding GCase Substrates in Parkinson’s Disease: Perspectives... Read more


vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions (IROS), a leading United Arab Emirates (UAE)-based contract research organization, has been submitted to the... Read more


Acadia Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026

SAN DIEGO / Dec 18, 2025 / Business Wire / Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Catherine Owen Adams, Chief Executive Officer will represent the company in a session scheduled on Tuesday, January 13, 2026, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live webcast of Acadia’s presentation will be accessible on the company’s website, acadia.com,... Read more


Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San Francisco. The live webcast will be available in the investor section of the company's website at www.beamtx.com... Read more


Alpha Tau Medical to Present at the J.P. Morgan 2026 Healthcare Conference

The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones  JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 2026 Healthcare... Read more


DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

MINNEAPOLIS / Dec 18, 2025 / Business Wire / DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA’s request... Read more


Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3β (GSK-3β), today announced that data from its Phase 2 study evaluating elraglusib in metastatic pancreatic cancer have been selected for an... Read more


Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass., Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™... Read more


Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway  Isaralgagene civaparvovec continues to show favorable safety and tolerability profile Sangamo expects to complete Biological License Application (BLA) submission under accelerated approval... Read more


Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus

Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis caused by norovirus infection There are no approved treatments or vaccines currently available for norovirus infection BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the... Read more


Incyte to Present at Upcoming Investor Conference

WILMINGTON, Del. / Dec 18, 2025 / Business Wire / Incyte (Nasdaq:INCY) announced today that it will present at the 44th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with... Read more


Nutriband Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

The LOI Aligns with Federal Priorities on Fentanyl Crisis, Artificial Intelligence, and Quantum Technology ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta LLC... Read more


Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BALA CYNWYD, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will present and participate in 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference, taking place in San Francisco, CA from January 12 – 15, 2026. Details on the... Read more


Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members of the Replimune management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2025 at 1:30 PM PT. A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A... Read more


CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath

DefenCath® demonstrated a 72% reduction in CRBSI and 70% reduction in hospitalizations secondary to CRBSI BERKELEY HEIGHTS, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced interim results for the Company’s ongoing real-world evidence study being conducted in conjunction with U.S. Renal... Read more


Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071 There were no treatment-related laboratory findings, no safety findings, and no treatment-related serious adverse events (SAEs) Exploratory quantitative electrophysiology results suggest OV350 had central activity and spectral power consistent with expected physiological effects of KCC2 modulation; aligned with expected... Read more


Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with resectable pancreatic ductal adenocarcinoma... Read more


Soligenix: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the results from its Phase 2a proof... Read more


Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series... Read more


Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has requested the European Medicines Agency (“EMA”)... Read more


ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 Cambridge, Massachusetts, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development... Read more


REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, Md., Dec. 18, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference. Presentation DetailsDate and Time: Wednesday, January 14, 2026 at 10:30 a.m. PT Location: Westin St. Francis, San Francisco, CA A live webcast of the presentation can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available... Read more


Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Athira... Read more


Halozyme Therapeutics: U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer

RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U.S. Food and Drug Administration (FDA) for RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj), which is co-formulated with ENHANZE® for patients with epidermal growth factor receptor (EGFR)-mutated locally... Read more


Mind Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

NEW YORK / Dec 18, 2025 / Business Wire / Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that Rob Barrow, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 2:15 p.m. PT. “It is a privilege to participate in the J.P.... Read more


CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure Partnership strengthens global preparedness against a significant pandemic threat If licensed and in the event of an influenza pandemic, Moderna will allocate 20% of its H5 pandemic vaccine manufacturing capacity for timely supply to low- and middle-income countries at affordable pricing OSLO, NORWAY and CAMBRIDGE, MA / ACCESS Newswire / December... Read more


Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in combination with KEYTRUDA® (pembrolizumab) in 1L/2L+ R/M HNSCC at 3.6 mg/kg and 4.4 mg/kgUpdated data from ongoing Phase 1 monotherapy study in 2L+ R/M HNSCC expected mid-2026; updated data from ongoing Phase 1/2 study evaluating MICVO in combination with KEYTRUDA®, including... Read more


CAMP4 Therapeutics and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4 to receive $17.5 million upfront and eligible for additional milestone-based payments, in addition to tiered royalties CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company... Read more


Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified endpoint The reduction in GluSph in CSF, a first-ever observation following the administration of a GCase modulator to PD patients, suggests increased GCase activity in the brain, which is expected to impact the progression of Parkinson’s disease (PD) KOL event planned for early January to discuss the results; registration... Read more


Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination

The combination of denifanstat and resmetirom was generally well-tolerated Pharmacokinetic (PK) results support further development of the combination A Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic... Read more


Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological and psychiatric disorders, today announced that management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 11:15 a.m. PST / 2:15 p.m.... Read more


MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successful completion of patient enrollment in the randomized, placebo-controlled Phase 2 clinical trial, the OXTOX study (Oxaliplatin Neurotoxicity study in patients with metastatic colorectal cancer). This study, an investigator-initiated... Read more


BioNTech Closes Acquisition of CureVac Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech has completed its exchange offer to acquire CureVac Acquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing In total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganization CureVac will continue to operate under... Read more



Biodexa Pharmaceuticals Announces Pricing of $10 Million Public Offering

December 18, 2025 - Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (“Biodexa” or the “Company”), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of a best efforts public offering of an aggregate of (i) 157,000 units (the “ADS Units”), with each unit consisting of (A) one American depositary share (representing 100,000 of the Company’s ordinary... Read more


Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company

WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 to an insider of the Company. The net proceeds... Read more


Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement for aggregate gross proceeds of C$177,500 (the “Private Placement”). The Private Placement consisted of the... Read more


Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company’s Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will... Read more


PureTech Health Appoints Robert Lyne as Chief Executive Officer

BOSTON / Dec 18, 2025 / Business Wire / PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announces that the Board of Directors has appointed Robert Lyne as Chief Executive Officer (CEO), and as a member of the Board of Directors, effective immediately. Robert Lyne commented: “I’m honored to lead PureTech as CEO at such... Read more


Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present the Company’s latest developments and outlook for 2025 at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15 in San... Read more


Microbix Biosystems Reports Results for Q4 and Fiscal 2025

Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“2025” and “Q4”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay... Read more


Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured... Read more


Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC) Novel Anti-Fibrotic Preclinical Findings: Oral presentation on Saturday, February 21, 2026, “Obefazimod shows first evidence of anti-fibrotic activity in preclinical... Read more


Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026  Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks  NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused... Read more


Insmed Provides Clinical and Business Update

Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications BRIDGEWATER, N.J., Dec. 17, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a people-first global biopharmaceutical company striving to deliver first- and be... Read more


Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved for eligible patients in Europe with relapsed or refractory FL Patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide in the Phase 3 inMIND registration trial In Western countries, including Europe, relapsed... Read more


Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy

The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of life Female sexual dysfunction is an extremely common unmet medical need which can have a major impact on quality of life in otherwise healthy women Longeveron anticipates entering into licensing or partnering agreements for the potential development and... Read more


Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by End of 2027 CHAPEL HILL, N.C., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase... Read more